Bionano Genomics Posts 12% Revenue Growth, Warns on Funding

Bionano Genomics, Inc. posted 12% third-quarter revenue growth and a narrower net loss, but management said continued operations depend on raising additional funding amid expected losses and negative cash flows.

Revenue for the quarter ended Sept. 30 was $8.28 million. Net loss narrowed to $6.45 million from $8.50 million a year earlier.

Consumables revenue increased 24% to $4.7 million, and flowcell sales rose 18% to 9,870. Gross margin reached 48%, up from 46%, while operating expenses fell 12% to $10.5 million.

At Sept. 30, the company had $4.4 million in cash and cash equivalents and $3.8 million in short-term investments. It used $14.9 million in cash for operating activities during the first nine months of 2026.

Management said expected losses and cash outflows created substantial doubt about whether Bionano could continue operating for 12 months after the quarterly report was issued. It said continued operations depend on raising additional funding. Bionano reiterated its full-year 2026 revenue guidance of $31 million to $33 million.